Dashboard
Manage Tickers

CLDX Celldex Therapeutics, Inc.

Nasdaq celldex.com


$ 26.56 $ -0.79 (-2.89 %)    

Thursday, 16-Oct-2025 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 26.55
$ 27.53
$ 22.65 x 20
$ 28.28 x 45
$ 26.17 - $ 27.89
$ 14.40 - $ 29.93
773,773
na
1.76B
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 02-26-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-07-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-07-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-14-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 02-23-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

analyst-expectations-for-celldex-therapeuticss-future
Analyst Expectations For Celldex Therapeut...
10/13/2025 20:01:52

barclays-initiates-coverage-on-celldex-therapeutics-with-underweight-rating-announces-price-target-of-25
Barclays Initiates Coverage On Celldex The...
10/13/2025 12:17:38

Barclays analyst Etzer Darout initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Underweight rating and announc...

5-analysts-assess-celldex-therapeutics-what-you-need-to-know
5 Analysts Assess Celldex Therapeutics: Wh...
09/17/2025 14:01:35

canaccord-genuity-maintains-buy-on-celldex-therapeutics-maintains-62-price-target
Canaccord Genuity Maintains Buy on Celldex...
09/17/2025 13:35:57

Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $62 price target.

celldex-presents-phase-2-data-showing-barzolvolimab-improves-chronic-spontaneous-urticaria-independent-of-baseline-immunoglobulin-e-levels-at-eadv-2025
Celldex Presents Phase 2 Data Showing Barz...
09/17/2025 09:14:33

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/08/2025 21:07:27

wells-fargo-maintains-overweight-on-celldex-therapeutics-lowers-price-target-to-38
Wells Fargo Maintains Overweight on Cellde...
08/20/2025 18:47:53

Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target...

citigroup-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-48
Citigroup Maintains Buy on Celldex Therape...
08/20/2025 16:06:40

Citigroup analyst David Lebowitz maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $5...

celldex-therapeutics-pulls-plug-on-eosinophilic-esophagitis-investigational-drug-as-data-falls-short
Celldex Therapeutics Pulls Plug On Eosinop...
08/20/2025 14:22:16

Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but...

what-analysts-are-saying-about-celldex-therapeutics-stock
What Analysts Are Saying About Celldex The...
08/20/2025 14:01:48

canaccord-genuity-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-62
Canaccord Genuity Maintains Buy on Celldex...
08/20/2025 13:54:53

Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target fr...

la-z-boy-posts-downbeat-q1-results-joins-james-hardie-industries-alcon-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
La-Z-Boy Posts Downbeat Q1 Results, Joins ...
08/20/2025 12:27:54

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/20/2025 12:08:41

why-rocket-pharmaceuticals-shares-are-trading-higher-by-over-15-here-are-20-stocks-moving-premarket
Why Rocket Pharmaceuticals Shares Are Trad...
08/20/2025 11:24:03

hc-wainwright--co-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-42
HC Wainwright & Co. Maintains Buy on Celld...
08/20/2025 10:42:56

HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the pric...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/19/2025 21:06:03

celldex-reports-phase-2-topline-results-for-barzolvolimab-in-eosinophilic-esophagitis-says-study-met-primary-endpoint-demonstrating-barzolvolimabs-ability-to-potently-deplete-mast-cells-in-gastrointestinal-tract
Celldex Reports Phase 2 Topline Results Fo...
08/19/2025 20:03:35

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported topline results from the Company's ongoing Phase 2 study of barzolv...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
08/13/2025 17:35:30

celldex-therapeutics-q2-eps-085-misses-083-estimate-sales-730000k-miss-1007m-estimate
Celldex Therapeutics Q2 EPS $(0.85) Misses...
08/07/2025 20:45:15

celldex-therapeutics-13g-filing-shows-point72-asset-management-reported-a-67-stake-in-co-as-of-july-2-2025
Celldex Therapeutics 13G Filing Shows Poin...
07/10/2025 20:14:20

- SEC Filing

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION